Evidence map›Paper›PMID 38340539›Full record

ArticlePsychoneuroendocrinology2024

Olanzapine's effects on hypothalamic transcriptomics and kinase activity.

Sandra Pereira, Laura N Castellani, Chantel Kowalchuk, Khaled Alganem, Xiaolu Zhang, William G Ryan, Raghunath Singh, Sally Wu, Emily Au, Roshanak Asgariroozbehani and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychoneuroendocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Sandra PereiraCentre for Addiction and Mental Health, Toronto, ON, Canada; Department of Physiology, University of Toronto, Toronto, ON, Canada.
Laura N CastellaniCentre for Addiction and Mental Health, Toronto, ON, Canada.
Chantel KowalchukCentre for Addiction and Mental Health, Toronto, ON, Canada.
Khaled AlganemDepartment of Neurosciences, University of Toledo, Toledo, OH, USA.
Xiaolu ZhangDepartment of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
William G RyanDepartment of Neurosciences, University of Toledo, Toledo, OH, USA.
Raghunath SinghCentre for Addiction and Mental Health, Toronto, ON, Canada.
Sally WuCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Emily AuCentre for Addiction and Mental Health, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada.
Roshanak AsgariroozbehaniCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Sri Mahavir AgarwalCentre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Banting & Best Diabetes Centre, Toronto, ON, Canada.
Adria GiaccaDepartment of Physiology, University of Toronto, Toronto, ON, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; Banting & Best Diabetes Centre, Toronto, ON, Canada.
Robert E MccullumsmithDepartment of Neurosciences, University of Toledo, Toledo, OH, USA; ProMedica, Neuroscience Institute, Toledo, OH, USA.
Margaret K HahnCentre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Banting & Best Diabetes Centre, Toronto, ON, Canada. Electronic address: margaret.hahn@camh.ca.
Centre for Addiction and Mental Health · CAUniversity of Toledo · USDiabetes Canada · CALouisiana State University Health Sciences Center Shreveport · USUniversity of Toronto · CA

Funding

Translational assessment of brain bioenergetic function in schizophreniaR01MH121102 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI MARANO, CHRISTOPHER, MCCULLUMSMITH, ROBERT E · 2020 to 2024
$3.7M
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's DiseaseR01AG057598 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SCHIEFER, ISAAC T · 2018 to 2022
$2.3M
Cell-specific analysis of sub-kinomes in schizophreniaR01MH107487 · NIMH · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MCCULLUMSMITH, ROBERT E, MELLER, JAREK · 2016 to 2020
$1.9M
Training in Molecular and translational Cell DynamicsT32GM144873 · NIGMS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI AVIDOR-REISS, TOMER, DWORKIN, LANCE DOUGLAS · 2022 to 2024
$1.3M
NIA NIH HHS R01 AG057598NIGMS NIH HHS T32 GM144873NIMH NIH HHS R01 MH107487NIMH NIH HHS R01 MH121102
6 · The paper itself

Abstract

Olanzapine is a second-generation antipsychotic that disrupts metabolism and is associated with an increased risk of type 2 diabetes. The hypothalamus is a key region in the control of whole-body metabolic homeostasis. The objective of the current study was to determine how acute peripheral olanzapine administration affects transcription and serine/threonine kinase activity in the hypothalamus. Hypothalamus samples from rats were collected following the pancreatic euglycemic clamp, thereby allowing us to study endpoints under steady state conditions for plasma glucose and insulin. Olanzapine stimulated pathways associated with inflammation, but diminished pathways associated with the capacity to combat endoplasmic reticulum stress and G protein-coupled receptor activity. These pathways represent potential targets to reduce the incidence of type 2 diabetes in patients taking antipsychotics.

Indexed as

Antipsychotic AgentsDiabetes Mellitus, Type 2AnimalsBenzodiazepinesGene Expression ProfilingHumansHypothalamusOlanzapineRatsAntipsychotic AgentsBenzodiazepinesOlanzapineKinome arrayOlanzapineRNA-seq

Identifiers

PMID38340539
PMCPMC10947847
OpenAlexW4391578023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.